Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Oncologist|March 29, 2011
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewDorothy Keefe, Joanne Bowen, Rachel Gibson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 16, 2015
Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapyChristina H Ruhlmann, Trine Zeeberg Iversen, Meena Okera, et al.
BJU International|December 16, 2010
Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610Meena Okera, Kyoungwha Bae, Eric Bernstein, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
Case Reports in Oncological Medicine|August 9, 2014
Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma PatientsStephanie Du Four, Angela Hong, Matthew Chan, et al.
Breast Cancer Research and Treatment|August 1, 2022
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancerElgene Lim, Frances Boyle, Meena Okera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
JAMA Oncology|September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical TrialGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast CancerPatrick Neven, Stephen R D Johnston, Masakazu Toi, et al.
Pageof 2